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Introduction 
Pro renin is a polypeptide with a molecular weight of approxi ma tely 
56 ,000 daltons ( 3,73,75,78) having no inherent enzymatic activity. 
It does, however, have the potential for renin-like properties which 
occur when prorenin is exposed to the correct environment and the 
proper structural changes take place. Sine 1971 when Lumbers (45) 
discovered prorenin, activation of the molecule has been demonstrated 
by a number of methods including cryoacti vation, acid dialysis and 
exposure to proteolytic enzymes. Much of the research aimed at under¬ 
standing the physiologic role of prorenin, if any, has been done by ana¬ 
lyzing the possible mechanisms for this activation (see Apoendix I). 
Evaluation of the prorenin system has proven to be a complex problem 
Plasma is an enormously complicated medium and assigning a unique role 
to any one component is foolhardy. Conversely, experimental data 
obtained from more limited systems is not easily applied to physiological 
conditions. Interspecies differences have also complicated the under¬ 
standing of prorenin. Trypsin activation of prorenin has never been well 
documented in the rat (57), a commonly used animal model for hypertension 
An understanding of the prorenin system of the rat is important in 
interpreting past experiments and in elucidating the possible significanc 
of proreni n. 
The objective of this research is to demonstrate the presence of 
inducible plasma renin activity in rat plasma and to show that this 
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increased activity is secondary to renin formation from prorenin. The 
first step is proof that inducible renin activity exists in rat plasma, 
both from normal and nephrectomi zed rats. This will be accompli shea 
by use of trypsin as an activator of angiotensin I production. Increased 
generation in normal rat plasma would show presumed activation of pro renin 
as has been done in other species. Since there is no circulating 
active renin 24 hours after nephrectomy in rats and other animals (70), 
demonstration of increased activity in the plasma of nephrectomi zed 
animals would eliminate the possibility of any alteration in endogenous 
active renin as a source for increased angiotensin I production. It 
would also support an extra-renal source for at least a portion of 
circulating prorenin. 
While renin's sole function appears to be the production of angiotensin I, 
there are other sources of angiotensin I generation under the right 
conditions. Thus, angiotensin I measurement and renin activity cannot 
be assumed to be synonymous. Therefore, the second aspect of investiga¬ 
tion is an attempt to show renin to be the source of elevated angiotensin I 
levels. This will be done in two ways. The profile of angiotensin I 
generation with variation of pH will be examined in an attempt to show 
the "fingerprints" of renin activity. Secondly, the hemodynamic properties 
of activated plasma will be evaluated by injection of this plasma into 
animals prepared for blood pressure monitoring (bioassay animals). The 
effects of specific pharmacological blockade will help to characterize 
the reasons for any blood pressure alterations. 
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Materials and Methods 
Plasma samples - Plasma was collected from donor animals by 
cannulation of the carotid artery of male and female Sprague-Dawl ey 
rats weighing 200-300 grams; all plasma was pooled. Ketalar (ketamine 
HC1 , Parke-Davis) 50mg/kg i ntraperi zoneally was used for anesthesia. 
Bioassay animals - Animals were male and female Sprague-Dawl ey 
rats weighing 200-300 grams. Surgical preparations are described 
below. 
Plasma renin activity - Activity was determined at pH 6.0 by 
the Renak renin RIA kit (Roche). EDTA, PMSF and 8-hydroxyqui nol i ne 
were used as angiotensinase inhibitors. All plasma was stored at -40 C 
and thawed in an ice bath just prior to assay. There was no multiple 
thawing and refreezing. 
Trypsin activation - Trypsin solution was prepared by addition 
of lypholized enzyme (Sigma) to 0.001N HC1 . Fresh trypsin solution was 
prepared each day of use. Trypsin activation was done with 1 mg enzyme/ml 
plasma unless otherwise noted. Activation was done at 4"c for 48 hours. 
Plasma was dialyzed against 0.1 M Tris buffer in normal saline (pH 7.4) 
througnout the activation, as was control plasma. 
Renin activity pH profile - Plasma pH profile was obtained by the 
method of Gallagher (25). Plasma, following 48 nours of dialysis, was 
adjusted to the desired pH by addition of 0.01 N malaeic acid or 2.ON K0H. 
Plasma renin activity was then determined by RIA as described above with 
the exception that addition of MES-HC1 buffer was omi tied. 
Nephrectomy and adrenalectomy - Both procudures were oerformed 
under ether anesthesia. Nephrectomy procedures were identical for donor 
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and bioassay animals. Bilateral incisions were made just below the 
costal margins and the organs were isolated. Ureters and renal vessels 
were clamped and ligated prior to removal of kidneys. Excision of 
adrenal glands (in the case of bioassay animals) without ligation gave 
no significant hemorrhage. Following surgery, food was withheld and 
water (or normal saline for adrenalectomized rats) was provided ad lib. 
Adrenalectomized rats also received 0.5mg deoxycorticosterone SC at the 
time of surgery. Both operations were done 24 hours before plasma was 
collected or blood pressure recording was done. 
Blood pressure monitoring - Bioassay animals were anesthetized 
with Ketalar (50mg/kg IP) and a tracheotomy was performed. Blood 
pressure monitoring was done by cannulation of the common carotid artery 
with PE50 Intramedic polyethylene tubing filled with heparinized saline. 
Recording was done using a Narco Physiograph and a Slather P23dB transducer. 
The vagus nerve was not severed. For IV administration, one or both 
internal juglar veins were cannulated using tubing of known dead space. 
Hemodynamic experiments - Each j_n vivo experiment began with 
injection of 200ng of angiotensin I to insure proper operation of 
equipment and normal responsiveness of the animal (brief, rapid increase 
in blood pressure). The ganglionic blocker pentolinium (Ansolysen, Wyeth) 
was used, lOmg/kg IP, except under conditions denoted as "baseline." 
Saralasin (l-sar-8-ala-angiotensin II, 120ug/ml), when used, was admini¬ 
stered at 0.044ml/min via a constant infusion pump beginning ten minutes 
prior to other studies and was continued throughout. Effective blockade 
was always demonstrated by lack of a pressor response to 200ng of 
angiotensin I. For alpha-adrenergic blockade, phentolamine (Regetine, CI5A) 
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was slowly administered IV (1 mg/kg). Blockade was shown by absence 





Trypsin activation - Exposure of plasma to trypsin yielded 
approximately a doubling of angiotensin I production at pH 6.0. This 
increase occurred in the plasma of normal and neph rec tomi zed animals. 
Further analysis showed a linear increase in plasma renin activity with 
increasing trypsin concentration up to 2mg trypsin/ml plasma. At 
0.1 mg/ml , however, an unexpectedly sharp rise is present (graph 1). This 
is seen clearly in normal plasma and not in plasma from nephrectomi zed 
rats. 
pH optima - Plots of plasma renin activity with varying pH did 
not yield the classic smooth curve of renin (graph 2). The low pH 
range showed surprisingly high levels of angiotensin I generation with 
increasing production as pH decreased. The mid pH range (5.0 to 7.0) was 
composed of a gradual increase in activity with lowering of pH and a peak 
at about 5.5. In trypsin treated samples, there is also a peak of 
activity at pH 7.5. With the exception of pH 4.0, activity of untreated 
plasma was always greater than that of trypsin treated plasma from 
nephrectomi zed animals and activity of normal plasma which was trypsin 
activated was greater than either of the other sample groups at correspond- 
ing pH. 
Hemodynamic studies - Introduction of 0.1 ml of dialyzed, untreated 
plasma into a bioassay animal had no effect on blood pressure. Injection 
of trypsin treated plasma from nephrectomi zed or normal rats yielded a 
characteristic biphasic response comDosed of a rapid drop in pressure 
(phase A) followed by a slow rise to baseline. After a brief delay 
(1-2 minutes), a mild pressor effect was noted (phase 8), after which olood 
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pressure returned to baseline. Quantitative summarization of results 
can be found in tables 1 and 2. Graphic representation is located in 
graphs 3, 4 and 5. No differences were noted between injection of 
treated plasma from normal versus nephrectomi zed donor animals. Plasma 
of nephrectomi zed rats was generally used since it contained no inherent 
renin activity prior to activation. 
The phase B rise in blood pressure above baseline was equal in 
normal and nephrectomi zed bioassay animals. A greater sensitivity to 
angiotensin I would not have been surprising in nephrectomi zed animals 
since their plasma should not contain any active renin. In an attempt 
to show renin dependence of this pressure peak, saralasin was administered 
prior to plasma injection. In spite of the elimination of a response 
to angiotensin I, no change could be detected in the phase B phenomenon 
(table 6). The pressor response was totally eliminated, however, by 
preliminary treatment wi th phentol ami ne . Prior adrenalectomy of bioassay 
animals also obliterated the rise in pressure; administration of 
phentol amine to adrenal ectomi zed animals had no additional effect. 
While an initial drop in blood pressure following plasma injection 
(phase A) was a fairly consistent finding, different experimental 
conditions were noted to modulate this response. A comparison of 
adrenal ectomi zed rats with and without pentolinium snows that those with 
pentolinium had a significantly smaller drop in pressure. Another incon¬ 
sistency noted was that rats treated with pentolinium and phentol amine 
did not always respond to treated plasma with a statistically significant 
drop in pressure. Animals treated with only pentolinium had significant 




These experiments clearly document an increase in angiotensin I 
generation following trypsin treatment. In both types of plasma (that 
from normal and nephrectomized donor animals) production of angiotensin I 
is doubled when measured at pH 6.0. Thus, inducible angiotensin I 
generation exists in rat plasma. Because this was the case in plasma 
from nephrectomized animals, alteration of endogenous active renin 
cannot account for this increase in activity. Although active renin 
is no longer present in animals 24 hours after nephrectomy, prorenin 
appears to be present in near normal levels (65,66). Anephric patients 
also continue to have circulating plasma prorenin (9,76). If the increase 
in angiotensin I activity demonstrated in this work proves to be renin, 
this would be strong support for a non-renal source of prorenin in the 
rat. 
The degree of increased production is generally linearly corre¬ 
lated to the concentration of trypsin used during incubation. This 
linear relationship, however, did not hold at O.lmg trypsin/ml of plasma, 
where a disproportionate increase in activity was noted. We cannot 
explain this increase. 
Having demonstrated that increased angiotensin I levels could be 
induced by trypsin, the next step was an attempt to prove it came from 
renin. Profiles of renin activity with variation of pH revealed a 
group of curves not typical of plasma renin activity (peak at pH 5.5-6.0 
with a smooth fall off on either side (25,46,69)). Angiotensin I pro¬ 
duction at low and mid pH ranges were similar among different groups 
tested, independent of whether trypsin activation was carried out. In 
the pH range of 5.0-6.5, activity was somewhat like that of renin in 
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that a production peak was present at pH 5.5-6.0 with a decrease in 
activity moving away from that point. Another peak of angiotensin I 
generation was present at pH 7.5 and was dependent on the plasma 
sample having been treated with trypsin. 
The results of pH profiling do not support the assumption that 
angiotensin I production is the result of renin or that trypsin 
specifically increases active renin content. The facts that part of 
the curves are similar to that of renin and that the newly created activity 
might have resulted from the cleavage of prorenin where no circulating 
active renin was originally present, however, justified an attempt to 
look at the hemodynamic effects of the activated plasma to see if these 
were characteristic of renin. Activated plasma from nephrectomized donor 
animals was generally used to overcome any potential difficulty in 
separating the effects of endogenous renin from newly activated renin. 
Hemodynamic experimentation with injection of activated plasma into 
bioassay animals yielded complicated and rather unexpected results. 
If renin is injected, one would expect a rapid rise in pressure (5) 
but such was not the case; the initial cardiovascular event was a fall 
in blood pressure (phase A). While a rise in pressure above baseline 
did occur consistently (phase B), it was after a significant delay. 
Additional and more persuasive evidence against this pressor response 
being renin mediated is the demonstration that saralasin, an extremely 
effective blocker of the vasoconstrictive and pressor actions of angio¬ 
tensin II (29), did not prevent this response. Adequate blockade was 
always demonstrated prior to each experiment. Therefore, specific block¬ 
ing studies also failed to support the presence of active renin in 
trypsin activated plasma. 
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What can be inferred from the results of the blocking experiments? 
Once the phase B pressor effect was shown not to be due to renin, 
the contribution of other possible mediators was investigated. The rise 
in blood pressure was consistently eliminated by pretreatment with 
phentolamine. Phentolamine is a moderately effective alpha-adrenergic 
blocker (20). While angiotensin II may in some way potentiate the 
pressor effect of catecholamines (8), phentolamine does not seem to 
alter the interaction of angiotensin analogues with its receptor (79). 
Thus, the effect of phentolamine can be interpreted as evidence that 
phase B may be due to catecholamines. The observation that adrenal¬ 
ectomy is as effective as phentolamine in preventing a rise in blood 
pressure would also implicate catecholamines, particularly those from 
the adrenal. 
Bradykinin, too, can stimulate adrenal catecholamine release 
(22,23,59). The initial fall in blood pressure followed by a catechol¬ 
amine mediated pressure rise would be consistent with activation of the 
kinin system. Kal1ikrein may have a role in prorenin activation (see 
Appendix I). It should be noted that angiotensin II receptros controlling 
epinephrine and norepinephrine release from the adrenal medula may be 
less specifically blocked by saralasin than those receptors governing 
vascular tone (26). Angiotensin II also has the capability to stimulate 
adrenal catecholamine release (22,23,59), so lack of phase B modulation 
by saralasin does not totally rule out some contribution of renin in 
the production of the hypertensive response. 
The etiology of the phase A hypotensive period following plasma 
injection is uncertain. The involvement of the kinin system seems 
like a reasonable possibility, although the large changes in blood 
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pressure with the rapid time course being discussed would call for 
vast kinin activation. There is evidence that trypsin can activate 
kallikrein (78). No evidence was generated in these experiments to 
lend support to this model. 
In rats treated with pentolinium and phentolamine, the typical 
hypotensive episode did not always reach statistical significance. 
There is no obvious explanation for this. Most likely, the lowering 
of baseline pressure brought about by phentolamine attenuated further 
vasodilation. Phentolamine has its own vasodilatory action independent 
of alpha blockade (20). The reason why normal bioassay animals had 
significant pressure drops during phase A when pretreated with phentolamine, 
in spite of having baseline pressure lowered similarly to nephrectomized 
and adrenalectomized bioassay rats, is unknown. 
Pentolinium was given routinely to animals in an effort to achieve 
a clearer baseline pressure. Its use gave only a small decrease in 
baseline pressure. While ganglionic blockers have variable effects on 
blood pressure based on the extent of autonomic discharge at the time 
of use, they generally produce only mild reductions in pressure; postural 
hypotension is a more significant and consistent effect (47). Ganglionic 
blockers also reduce reflex accommadation to exogenously administered 
substances. Use of these blockers is a standard technique in bioassay 
systems (5). In only one situation did results from baseline (untreated) 
and pentolinium treated animals differ. The fall in blood pressure 
following injection of trypsin treated plasma to adrenalectomized rats 
vvas greater in controls than with pentolinium. 
One difference between past studies using trypsin activation and 
these experiments is that activation was carried out over a longer 
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period of time in the present work. Instead of minutes to a couple of 
hours, trypsin was incubated with the plasma for 48 hours. Most evidence 
seems to support activation being a very rapid process, perhaps even 
terminating within a few minutes (9,69). The effect of prolonged 
incubation should only result in a guarantee of full dialysis. The 
sudden peak in the trypsin titration curve (graph 1) at low trypsin 
concentration does raise the possibility that higher concentrations 
with long incubation could be creating angiotensin I by some other 
route (see below and figure 1). 
Was renin generated by the action of trypsin in these experiments? 
Based on these results, the answer is no. The possibility of prorenin 
activation, however, has not been absolutely eliminated. Relatively 
small renin pressor effects could nave been masked by the sharp phase A 
fall in pressure. Injection of activated plasma of normal rats, where 
there is pre-existing active renin, did not give a noticable increase 
in blood pressure. 
The lack of support for prorenin activation is surprising in view 
of ample evidence in the literature that, in some species, prorenin is 
converted to active renin. Plasma activation has been shown to correlate 
with the loss of a chromatographic protein peak felt to represent 
prorenin (3,7,50). Likewise, the peak known to correlate to renin 
undergoes an associated increase (3,7,50,71,75,78). Column fractions 
containing the prorenin peak have no innate renin activity (75). 
Looking at the kinetics of activated prorenin, several studies 
have shown that its Km is the same as that for plasma renin, regardless 
of the method of activation chosen (2,19,59,71). Vmax has been found 
to "'rcrease following trypsin treatment (59), showing an increase in 
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enzyme content without a change in allosteric activator or inhibitor 
concentration or a change in substrate affinity. 
Another fact in support of conversion of prorenin to renin is that 
activated prorenin appears to be immunologically identical to renin. 
Antibodies raised against renin inhibit the activity of both substances 
equally as effectively (71,72). 
Given the lack of evidence for prorenin activation being responsible 
for increased angiotensin I production, other possible sources must 
be considered. There are enzymes other than renin which can form 
angiotensin I under the proper conditions. Pseudorenin, for example, 
is a normal plasma constituent of both animals and man. It has the 
potential to directly hydrolyze human substrate to form angiotensin I, 
although this is normally totally inhibited in plasma (74). There is 
substantial evidence that pseudorenin is actually the protease cathepsin D. 
This enzyme has a pH optimum of about 4.5, significantly below that of 
renin. Dependence of apparent plasma renin activity on cathepsin D, or 
any other enzyme with a pH profile different from that of renin, would 
have been demonstrated by typical pH curves. The curve found was not 
typical of cathepsin D. 
Another pathway for production of angiotensin I independent of 
renin is unique to the use of trypsin as an activator. Tetradecapeptide 
(TCP) is a cleavage product of renin substrate. It has the potential 
to simulate angiotensin I in an RIA as well as to be quickly hydrolyzed 
to antiotensin I by both renin and cathepsin D. While trypsin does 
not appear to cleave TDP from human substrate (9,54,69), it does appear 
to have this capability ir dog plasma [25). TDP is a dialyzable peptide, 
so it should have been eliminated prior to assay in these experiments. 
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The formation of a non-dialyzable cleavage product with character!'stics 
similar to that of TDP cannot be ruled out. 
The results of pH profiling have already been reviewed. The 
increased activity in the area of pH 7.5 is present only in trypsin 
treated plasma and corresponds to the pH optimum of trypsin. Gallagher 
(25), doing similar experiments using dog plasma, also noted increased 
activity at this pH, although this also occasionally appeared in acid 
activated plasma. The data presented here would suggest some kind of 
direct participation of trypsin (i.e.-direct conversion of prorenin to 
renin, formation of a cleavage product similar to TDP). Another possi¬ 
bility is the involvement of another enzyme which has optimal activity 
at pH 7.5. Trypsin might unmask the effect of this enzyme; proteolytic 
activation of other enzymes has been recognized in the prorenin liter¬ 
ature (52). 
A shift in renin activity at low pH also appears in Gallagher's 
work. He attributes the increase in angiotensin I production to cathepsin D. 
Results from the present study do not show a peak at pH 4.5 as was 
found by Gallagher. Activity continued to rise through pH 4.0. Matoba 
(46) showed that a small synthetic molecule used as rat renin substrate 
gave a pH optimum of about 4.0 and a fall below that point. Conceivably, 
trypsin could form a cleavage product that would give pH profile results 
similar to this synthetic substrate. There is no data in this study 
to substantiate this postulate and the increase in low pH renin 
activity could be secondary to cathepsin D or some other acid protease. 
Trypsin activation of plasma consistently increases the production 
of angiotensin I. This is true not only -or plasma of normal rats but 
also in plasma of nephrectcmizad dcnor animals which contained no active 
renin prior to trypsin treatment. Profiles with variation of pH and 
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in vivo hemodynamic studies do not support a renin source for this 
increase generation. At the same time, the conversion of prorenin 
to renin has not been eliminated. Further investigation of tryDsin 
activation poses a dilemma. More isolated systems would be easier to 
understand but would also be further removed from physiologic conditions. 
Ultimately, chromatological isolation of the components of angiotensin I 
production will be necessary to fully characterize prorenin activation. 
Inconsistencies such as high levels of activation with low trypsin 
concentration must be analyzed. Once this work is accomplished, it 
can be augmented by in vivo experimentation as well as by clinical 
investigations dealing with interactions between prorenin and renin 
under varying normal and pathological conditions. It is only through 





Graph 1 EFFECT OF VARIABLE TRYPSIN CONCENTRATION ON PLASMA ANGIOTENSIN I 
PRODUCTION 
■*- plasma of normal donor animals 






















Graph 2: EFFECT OF pH ON PLASMA ANGIOTENSIN I PRODUCTION 
-O- plasma of normal donor animals + trypsin (1 mq/ml) 
-♦- - - plasma of normal donor animals without trypsin 
plasma of nephrectomized donor animals + trypsin (1 mq/ml) 






YSTOLIC 3L00D PRESSURE FOLLOWING INJECTION OF 0.1ml OF TRYPSIN 
iREATED PLASMA OF NEPHRECTOMIZED DONOR RATS INTO NORMAL BIOASSAY 
ANIMALS 
Drugs administered to bioassay animals: 
- none (baseline) 
— —-pentolinium 
— ♦ — ♦ pentolinium and phentolamine 























Graph 4: SYSTOLIC BLOOD PRESSURE FOLLOWING INJECTION OF O.lml OF TRYPSIN 
TREATED PLASMA OF NEPHRECTOMIZED DONOR RATS INTO NEPHRECTOMIZED 
BIOASSAY ANIMALS 
Drugs administered to bioassay animals: 
- none (baseline) 
—*-*— pentolinium 
pentolinium and phentolamine 























Graph 5: SYSTOLIC BLOOD PRESSURE FOLLOWING INJECTION OF O.lml OF TRYPSIN 
TREATED PLASMA OF NEPHRECTOMIZED DONOR RATS INTO ADRENALECTOMIZED 
BIOASSAY ANIMALS 
Drugs administered to bioassay animals: 
- none (baseline) 
— — — pentolinium 



























Table I: MEAN PHASE A FALL IN SYSTOLIC BLOOD PRESSURE INDUCED BY INJECTION 
OF O.lml DIALYZED TRYPSIN TREATED PLASMA OF NEPHRECTOMIZED ANIMALS 
Values given are mean+S.E. in mm of Hg. First number in parenthesies is the 
number of rats used to determine pressure values. Following is statistical 
significance of the change in pressure from baseline based on Student's t-test 
and Mann-Whitney Rank order test. These test aqree unless noted. 
*significant by Mann-Whitney test, p^.05. 
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able II: MEAN PHASE B RISE IN SYSTOLIC BLOOD PRESSURE INDUCED BY INJECTION 
OF 0.1ml DIALYZED TRYPSIN TREATED PLASMA OF NEPHRECTOMIZED ANIMALS 
alues given are mean±S.E. in mm of Hg. First number in parenthesies is the 
number of rats used to determine pressure values. Following is statistical 
significance of the change of pressure from baseline based on Student's 
t-test and Mann-Whitney Rank Order test. These tests agree unless noted. 
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Table III: COMPARISONS OF HYPOTENSIVE (PHASE A) EPISODES IN NORMAL, 
NEPHRECTOMIZED AND ADRENALECTOMIZED RATS WITH VARIATION OF 
DRUG MODULATORS 
Statistical significance based on Student's t-test and Mann-Whitney Rank 
Order test. Tests agree unless noted. 
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Table IV: COMPARISONS OF HYPERTENSIVE (PHASE B) EPISODES IN NORMAL, 
NEPHRECTOMIZED AND ADRENALECTOMIZED RATS WITH VARIATION OF 
DRUG MODULATORS 
Statistical significance based on Student's t-test and Mann-Whitney Rank 
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Table V: COMPARISON OF PHARMACOLOGICALLY MEDIATED DIFFERENCES OF BLOOD 
PRESSURE CHANGES ASSOCIATED WITH HYPOTENSIVE (PHASE A) EPISODES 
IN NORMAL, NEPHRECTOMIZED AND ADRENALECTOMIZED RATS 
Statistical significance based on Student's t-test and Mann-Whitney Rank 
order test. Tests agree unless noted, 
n.s. by Mann-Whitney test 
**d<..002 by Mann-Whitney test 
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Table VI: COMPARISON OF PHARMACOLOGICALLY MEDIATED DIFFERENCES OF BLOOD 
PRESSURE CHANGES ASSOCIATED WITH HYPERTENSIVE (PHASE B) EPISODES 
IN NORMAL, NEPHRECTOMIZED AND ADRENALECTOMIZED RATS 
Statistical significance based on Student's t-test and Mann-Whitney Rank 
order test. Tests agree unless noted. 
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Possible Mechanisms of Activation 
Many models for activation of prorenin have been put forward. 
It is far from certain which, if any, is correct, nor is it clear if 
different methods of induction are based on different molecular mechan¬ 
isms. Most models center on one of two concepts - direct action on 
the prorenin moleculare or removal of an inhibitory substance, thereby 
allowing activation to occur. All methods of induction seem to affect 
the same pool of prorenin. Acid treatment following cryoactivation (2) 
and pepsin following acid induction (71) do not add any further increase 
in renin activity. 
During acid activation, plasma is dialyzed to a pH of between 3.0 
and 3.5; activation does not occur if the final pH is greater than 4.5 
or less than 3.0 (71). Maximal activation depends on sufficient exposure 
to both acidic and relatively more alkaline environments (2). The 
combined process takes somewhat less than 24 hours for full effect (40). 
Acid activation is blocked by exposure to Trasylol (non-specific 
serine protease inhibitor) and soy bean trypsin inhibitor (19,40). It 
is also prevented by unacidified plasma (67). Treatment with N-ethylamiae, 
a thiol protease inhibitor, has no effect (67). Thus, acid activation 
requires the action of a serine protease. 
It appears to be appropriate to divide the process of acid activa¬ 
tion into two phases - acid and alkaline. Only about one-third of prorenin 
is activated during dialysis to pH 3.3 (68). It has been postulated 
that this part of activation is mediated by an acid protease. Cathepsin D 
has been thought of as a likely condidate because of its low optimal pH. 
It is also relativefy localized to the kidney, a more likely site for 
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physiologically significant activation than plasma. It is known that 
the enzyme is capable of activating renin (51). One problem with 
this theory is that no chromatographi cal ly isolatable protease seems 
to be involved; column isolation of prorenin does not consistently 
eliminate its capacity for acid activation (70). 
The remaining two-thirds of activation occur during the alkaline 
phase. It is this phase which is affected by serine protease inhibitors. 
Plasma can also block this phase; its inhibitory capacity is eliminated 
by prior acidification (70). Exposure to low pH appears to irreversibly 
destroy a protease inhibitor. Kotchen (37) collected plasma fractions 
containing neither renin nor renin substrate. Addition of certain fractions 
to an in vitro renin-renin substrate system gave significant reduction of 
angiotensin I generation. Prior acidification greatly reduces this 
inhibitory potential. Long chain, unsaturated fatty acids were already 
known to inhibit renin. Low pH was found to eliminate the capacity 
of arachidonic and linoleic acids to retard renin activity. Cold exposure 
did not prevent inhibition. The current model of cryoacti vation is 
basically equivalent to an isolated alkaline phase (2); the serine protease 
inhibitor that blocks the alkaline phase also blocks cryoacti vation. Low 
temperature has been shown to decrease the effectiveness of enzyme 
inhibitors (9). Thus, the proof of a fatty acid in the role of inhibitor 
is far from conclusive. Nor is it clear that disinhibi tion is the only 
mechanism responsible for acid activation. Hseuh (30) has noted that 
the acid phase of activation is not effected by dilution while the alkaline 
phase is modified. She has interpreted this to show a direct effect of 
acid on the prorenin molecule (such as changing hydrogen bonding). Hseuh 
also found that the extent of kallikrein activation of prorenin in a mixture 
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of normal and acid-exposed plasma was equal to the percentage of acid 
exposed plasma in the mixture. If activation were limited by inhibitors., 
then large percentages of untreated plasma should have prevented all 
activation and, conversely, excess kallikrein activity should have lead 
to total activation. These findings are consistent with a structural 
change in prorenin at low pH, making the molecule susceptible to 
modi fi cation. 
Trypsin activation is carried out at physiological pH; an optimal 
trypsin concentration of 0.5mg trypsin/ml plasma has been found in 
human plasma (53). Trypsin activation is also dependent on temperature. 
Trypsin is a very non-specific protease and its actions are far 
from limited to activation of prorenin. High doses of trypsin can 
yield a net decrease in renin activity secondary to destrction of renin 
substrate, other modifiers or even renin itself ( 25 ,53,57). Activation 
also appears to begin extremely quickly as lima bean trypsin inhibitor 
added prior to trypsi ni zation does not eliminate all activation (57). 
The action of trypsin may be more direct than that of acidification. 
Both trypsin and acid activation were equally inhibited by renin anti¬ 
bodies, substrate analouges and pepstatin (acid protease inhibitor); when 
prorenin was isolated by gel filtration, however, trypsin retained full 
activating potential while acid dialysis did not. Noth (53) added partially 
purified renin to plasma and then activated this plasma with trypsin. 
Activation resulted in a linear rise in angiotensin I production just like 
that of activated plasma without exogenous renin. Since there is no 
difference created by addition of exogenous renin, it can be inferred 




The body of data does not argue for direct action of trypsin on 
prorenin. Although trypsin can activate isolated prorenin, it is difficult 
to relate this to the in vivo process. It has also been shown that a 
protease can activate renin via an intermediary step (activation of an 
andogenous protease or degradation of inhibitor) (52). Other obser¬ 
vations lend support for such a process occuring with trypsin activation. 
Trypsin is normally about seventeen times more active at 37 C than at 
-4*C, yet it activates renin far better at -4 C than at the higher 
temperature (67). The fact that cold has been shown to decrease the 
potency of plasma protease inhibitors (1) makes this an attractive 
explanation, especially in view of the phenomenon of cryoactivation. 
Over the past few years, evidence has surfaced which suggests 
that kallikrein may be the activated (or disinhibited) protease of acid, 
and possibly trypsin, activation. Both urinary and pancreatic kallikrein 
have the capacity to activate semi purified prorenin (16), although 
activation in plasma is less predictable (16,56). Acid dialyzed plasma 
is much more susceptible to kallikrein activation, presumable secondary 
to destruction of an endogenous inhibitor (16,30,78). Kallikrein is not 
unique as a normal blood protease with this capacity, however; plasmin 
and other constituents can also activate prorenin (28). Kallikrein is a 
very potent activator, being fifty times more active than trypsin, even 
though trypsin is normally the more powerful protease (67). Combining 
this fact with the observation that renal kallikrein is distributed in 
roughly the same pattern as renin makes a model linking the two attractive. 
Sealey (67,69) found that, with patients on a random sodium intake and 
having normal plasma rer.in activities, there is a direct relationship 
between daily rate of urinary kallikrein excretion and the percentage of 
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the total plasma renin present as active renin. The authors hypoth¬ 
esize that this seems reasonable teleologically, bradykinin produc¬ 
tion maintaining local perfusion while prorenin conversion ultimately 
increases systemic angiotensin I levels. 
Genetic deficiences of various components of the kinin pathway 
allow further analysis of the system's role in renin activation. 
Sealey (68) showed that plasma deficient in either Hageman factor or 
prekal 1 ikrein almost totally lacks the alkaline phase during acid 
activation. Acid phase was unaltered. A one to one mixture of these 
two deficient plasmas gave near normal activation, suggesting dependence 
on both substances. Lack of a cofactor for contact activation of 
Hageman factor and prekal 1 ikrei n gave a diminished but present alkaline 
phase. Direct addition of purified plasma kail i krei n to plasma deficient 
in any component resulted in full correction of the activation abnormality. 
Thus, kail ikrei n may be the essential compound missing in these different 
samples. Nothin g can be concluded about the role of kal 1 ikrein in 
acid activation beyond that it appears to be obligatory. Other substances 
may also be necessary and the action of kail ikrein may be direct or 
indirect. Sealey has hypothesized that a kal 1 ikrein inhibitor is removed. 
The work of Hseuh (30) discussed earlier suggests that acid activation 
may structurally change prorenin, tnereby making it more susceptible to 
kallikrein's proteolytic activity. 
The discussion of activation has centered on the prorenin found in 
circulating plasma. Renal extracts contain large molecular weight renin 
differing from prorenin in molecular weight and in posessing some innate 
activity (6,7,11,24). Body (6) showed that a crude kidney extract 
separated on a column had two different pressure patterns on bioassay - 
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one the same as renin and one slower and more prolonged. Both produced 
angiotensin I. Acidification of the high molecular weight form changed 
its pressure tracing to that of normal renin. Incubation with 3M NaCl , 
1M Nal, 0.005% SDS and other denaturants had the same effect. The 
change in pressure tracing corresponded to a change in molecular weight 
from about 63,000 to that of normal renin. A substance eluted off the 
column was a protein capable of transforming normal renin back to the 
large form (24). Antibodies raised to this binding protein blocked 
this modification. These results were confirmed by Leckie and McConnell 
(39) who also showed that this inhibitor had no innate vasoactive proper¬ 
ties. There is some evidnece to suggest that binding is dependent on 
blockage of thio groups (34). The fact that this high molecular weight 
renin appears to be located in cellular granules in renal tissue suggests 
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